Evidence map›Paper›PMID 30654768›Full record

ArticleBMC cancer2019

Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases.

Justyna Sikorska, Damian Gaweł, Hanna Domek, Magdalena Rudzińska, Barbara Czarnocka

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Analysis of the Role of FRMD5 in the Biology of Papillary Thyroid Carcinoma.International journal of molecular sciences · 2021
    Article
  17. Article
  18. Review
  19. Review
  20. Prognosis Analysis and Validation of mFrontiers in oncology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Justyna SikorskaDepartment of Biochemistry and Molecular Biology, Center of Postgraduate Medical Education, Marymoncka 99/103, 01-813, Warsaw, Poland.
Damian GawełDepartment of Biochemistry and Molecular Biology, Center of Postgraduate Medical Education, Marymoncka 99/103, 01-813, Warsaw, Poland.
Hanna DomekDepartment of Biochemistry and Molecular Biology, Center of Postgraduate Medical Education, Marymoncka 99/103, 01-813, Warsaw, Poland.
Magdalena RudzińskaDepartment of Biochemistry and Molecular Biology, Center of Postgraduate Medical Education, Marymoncka 99/103, 01-813, Warsaw, Poland.
Barbara CzarnockaDepartment of Biochemistry and Molecular Biology, Center of Postgraduate Medical Education, Marymoncka 99/103, 01-813, Warsaw, Poland. bczarnocka@cmkp.edu.pl.ORCID http://orcid.org/0000-0001-7701-760X
Postgraduate School of Molecular Medicine · PL

Funding

The National Science Center 2012/07/B/NZ5/02444
6 · The paper itself

Abstract

backgroundPodoplanin (PDPN) is a mucin-type transmembrane glycoprotein specific to the lymphatic system. PDPN expression has been found in various human tumors and is considered to be a marker of cancer. We had previously shown that PDPN expression contributes to carcinogenesis in the TPC1 papillary thyroid cancer-derived cell line by enhancing cell migration and invasiveness. The aim of this study was to determine the effect of PDPN down-regulation in another thyroid cancer-derived cell line: BcPAP.

methodsIn order to determine the effects of PDPN on malignant features of BcPAP cells (harboring the BRAFV600E mutated allele) and TPC1 cells (carrying the RET/PTC1 rearrangement), we silenced PDPN in these cells using small interfering RNA (siRNA). The efficacy of PDPN silencing was confirmed by qRT-PCR and Western blotting. Then, we tested the motility and invasiveness of these cells (using scratch test and Transwell assay), their growth capacities F(cell cycle analysis, viability, clonogenic activity) and apoptosis assays), adhesion-independent colony-formation capacities, as well as the effect of PDPN silencing on MMPs expression and activity (zymography).

resultsWe found that PDPN-induced cell phenotype depended on the genetic background of thyroid tumor cells. PDPN down-regulation in BcPAP cells was negatively correlated with the migration and invasion, in contrast to TPC1 cells in which PDPN depletion resulted in enhanced migration and invasiveness. Moreover, our results suggest that in BcPAP cells, PDPN may be involved in the epithelial-mesenchymal transition (EMT) through regulating the expression of the ezrin, radixin and moesin (E/R/M) proteins, MMPs 9 and MMP2, remodeling of actin cytoskeleton and cellular protrusions. We also demonstrated that PDPN expression is associated with the MAPK signaling pathway. The inhibition of the MAPK pathway resulted in a decreased PDPN expression, increased E/R/M phosphorylation and reduced cell migration. Additionally, PDPN depleted BcPAP cells treated with inhibitors of MEK1/2 kinases (U0126) or of the BRAF V600E protein (PLX4720) had reduced motility, similar to that previously observed in TPC1 cells after PDPN knock-down.

conclusionsAltogether, our data suggest that PDPN may play an important role in the control of invasion and migration of papillary thyroid carcinoma cells in association with the E/R/M, MMPs and MAPK kinases.

Indexed as

ButadienesCell Line, TumorCell MovementCytoskeletal ProteinsEzrinGene Knockdown TechniquesHumansIndolesMAP Kinase Signaling SystemMatrix Metalloproteinase 2Matrix Metalloproteinase 9Membrane GlycoproteinsMembrane ProteinsMicrofilament ProteinsNeoplasm InvasivenessNitrilesButadienesCytoskeletal ProteinsEzrinIndolesMatrix Metalloproteinase 2Matrix Metalloproteinase 9Membrane GlycoproteinsMembrane ProteinsMicrofilament ProteinsMMP2 protein, humanMMP9 protein, humanmoesinNitrilesPDPN protein, humanPLX 4720PodoplaninradixinSulfonamidesU 0126BcPAPEzrin/radixin/moesinInvasivenessMetalloproteinasesMotilityPodoplaninTPC1

Identifiers

PMID30654768
PMCPMC6337816
OpenAlexW2916941649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.